CALU Monoclonal Antibody
-
中文名稱:CALU鼠單克隆抗體
-
貨號(hào):CSB-MA155030
-
規(guī)格:¥2621
-
其他:
產(chǎn)品詳情
-
產(chǎn)品描述:CALU單克隆抗體(CUSABIO貨號(hào):CSB-MA155030)是針對(duì)鈣連蛋白(Calumenin,CALU)研發(fā)的高特異性科研工具,適用于人、小鼠、大鼠等多物種研究。CALU作為鈣離子結(jié)合蛋白家族成員,廣泛參與細(xì)胞內(nèi)鈣穩(wěn)態(tài)調(diào)控、內(nèi)質(zhì)網(wǎng)蛋白質(zhì)折疊及細(xì)胞應(yīng)激反應(yīng)等關(guān)鍵生物學(xué)過程,其異常表達(dá)與心血管疾病、腫瘤發(fā)生等病理機(jī)制密切相關(guān)。本產(chǎn)品采用小鼠IgG1同型單抗(克隆號(hào)0B2C8),經(jīng)嚴(yán)格質(zhì)控驗(yàn)證其在ELISA和Western Blot(WB)實(shí)驗(yàn)中具有優(yōu)異性能,制劑濃度為1mg/mL,采用含0.02%疊氮化鈉的PBS緩沖液(50%甘油)穩(wěn)定保存,-20℃儲(chǔ)存條件下有效期達(dá)12個(gè)月。該抗體特別適用于研究CALU在疾病模型中的表達(dá)調(diào)控、信號(hào)轉(zhuǎn)導(dǎo)機(jī)制解析以及蛋白質(zhì)相互作用網(wǎng)絡(luò)研究,為心血管疾病分子機(jī)制、腫瘤微環(huán)境調(diào)控等基礎(chǔ)研究領(lǐng)域提供可靠檢測(cè)工具。通過優(yōu)化抗原表位識(shí)別區(qū)域,確保其在多種實(shí)驗(yàn)體系中呈現(xiàn)高靈敏度和低交叉反應(yīng)性,是進(jìn)行CALU相關(guān)蛋白功能研究和信號(hào)通路分析的理想選擇。
-
宿主:Mouse
-
反應(yīng)種屬:Human,Mouse,Rat
-
免疫原:Purified recombinant Human CALU(C-terminus) protein fragments expressed in E.coli.
-
免疫原種屬:Homo sapiens (Human)
-
克隆類型:Monoclonal
-
抗體亞型:IgG1
-
純化方式:Affinity purified
-
克隆號(hào):26H10
-
濃度:It differs from different batches. Please contact us to confirm it.
-
產(chǎn)品提供形式:Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium azide, 51% glycerol
-
應(yīng)用范圍:ELISA,WB
-
推薦稀釋比:
Application Recommended Dilution WB 1:500-1:5000 -
Protocols:
-
儲(chǔ)存條件:Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期:Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途:For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Most popular with customers
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
-